Strategies to enhance intracellular SIP levels by modulation of ceramidase and/or SPHK activities could be novel and promising therapeutic approaches to prevent tissues from IR injury during severe ischemia and following reperfusion. This evidence concerns the gene SPHK1 and ischemia.